Tempus

Tempus AI (NASDAQ: TEM) runs one of the largest clinical and molecular data operations in precision medicine. The company pairs genomic testing (oncology, hereditary) with software that puts AI insights into the clinical workflow. Its Tempus Next platform merges electronic medical record data with current clinical guidelines to flag care gaps, starting with lung cancer and expanding into breast cancer in 2025, with Mercy Health System as an early adopter. On the diagnostics side, Tempus reported studies validating algorithmic tests like Immune Profile Score and PurIST for guiding cancer treatment decisions. The company posted roughly $1.27 billion in 2025 revenue, up about 83% year over year, per its preliminary results.

Worth knowing: Tempus is a public company selling into a reimbursement-driven market, so its growth depends on payer coverage for its tests as much as on the AI itself. The data-licensing side of the business also means patient data flows into commercial products, which is disclosed but worth understanding.

Physicians order Tempus genomic tests through the Tempus portal or EMR integration. Health systems deploy Tempus Next by integrating it with their electronic medical record so it can surface guideline-based care gaps. Researchers can apply to programs like the PRECISION Challenge for access to foundation models and de-identified data.